Literature DB >> 12217254

Renal dysfunction as a cardiovascular risk factor.

Eberhard Ritz1, Ralf Dikow, Luis M Ruilope.   

Abstract

Indices of altered renal function (eg, microalbuminuria, increased serum creatinine concentration, or decrease in estimated creatinine clearance, particularly overt proteinuria) are independent predictors of cardiovascular morbidity and mortality. These parameters should be routinely evaluated in the elderly and in high cardiovascular risk populations, particularly when hypertension is present. Hypertensive kidney damage should be prevented by early aggressive treatment of hypertensive patients with microalbuminuria. To avoid further aggravation of high cardiovascular risk, antihypertensive agents devoid of unwanted metabolic side effects should be used. Epidemiologic information suggests that renal and cardiovascular outcome run parallel in this segment of the population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217254     DOI: 10.1007/s11906-002-0065-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  36 in total

Review 1.  Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension?

Authors:  V M Campese; S Bianchi; R Bigazzi
Journal:  Curr Opin Nephrol Hypertens       Date:  2000-03       Impact factor: 2.894

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

3.  Screening for renal disease using serum creatinine: who are we missing?

Authors:  L Duncan; J Heathcote; O Djurdjev; A Levin
Journal:  Nephrol Dial Transplant       Date:  2001-05       Impact factor: 5.992

4.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

Review 5.  Renal function: the Cinderella of cardiovascular risk profile.

Authors:  L M Ruilope; D J van Veldhuisen; E Ritz; T F Luscher
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity.

Authors:  H L Hillege; W M Janssen; A A Bak; G F Diercks; D E Grobbee; H J Crijns; W H Van Gilst; D De Zeeuw; P E De Jong
Journal:  J Intern Med       Date:  2001-06       Impact factor: 8.989

8.  "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis.

Authors:  R D Toto; H C Mitchell; R D Smith; H C Lee; D McIntire; W A Pettinger
Journal:  Kidney Int       Date:  1995-09       Impact factor: 10.612

9.  Kidneys and primary hypertension--initiators, stabilizers or/and victim-aggravators?

Authors:  B Folkow
Journal:  Blood Press       Date:  1994-07       Impact factor: 2.835

10.  Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients.

Authors:  E L Schiffrin; L Y Deng
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

View more
  2 in total

Review 1.  How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?

Authors:  Julian Segura; Helle Christiansen; Carlos Campo; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

2.  Cardiac disease in children with primary glomerular disorders-role of focal segmental glomerulosclerosis.

Authors:  Olanrewaju Adedoyin; Rachel Frank; Suzanne Vento; Marcela Vergara; Bernard Gauthier; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2004-02-10       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.